Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients

Figure 1 Quantitative changes in biochemical and virus markers in chronic hepatitis B patients after interferon therapy. A: ALT levels; B: HBV DNA levels; C: HBsAg levels; D: HBeAg levels; E: Anti-HBc levels. ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen.

Figure 2 Predictive models at baseline, 12, and 24 wk for hepatitis B e antigen seroconversion by 52 wk in hepatitis B e antigen-positive patients treated with interferon-α. A: Baseline; B: 12 wk; C: 24 wk. A change in each analyzed variable was assigned a score of 1. A score of 0 was given if patients did not have changes in any of the analyzed variables. The 3 factors correlating most with hepatitis B e antigen (HBeAg) seroconversion at each time point were used to build models to predict the outcome after interferon-α treatment.